Bliss GVS Pharma Share Price

NSE: BLISSGVS

₹ 464.60

+₹2.75 (0.60%)

Last updated 24 Jul, 2026, 15:40 IST

Bliss GVS Pharma Share Price Today

As of 25 Jul 2026, Bliss GVS Pharma share price is ₹464.60. The stock opened at ₹450.00, compared to its previous close of ₹461.85. During today's trading session, Bliss GVS Pharma share price moved in the range of ₹450.00 to ₹468.00, with an average price of ₹459.00 for the day. Looking at its last 52-week, the stock has touched a low of ₹118.00 and a high of ₹553.00. On the performance front, Bliss GVS Pharma share price has increased by 186.72% over the last six months and is up 204.00% on a year-on-year basis.

₹450.00

0.60% up today

₹468.00

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 9.90% QoQ

Latest Earning

Net Profit TrendUp by 49.31% QoQ

Latest Earning

Revenue TrendUp by 13.28% QoQ

Stock Performance

OutperformingBeat Nifty by 67.44 % in last 3 month

Shareholding Pattern

PromoterPromoter decreased stake by 0.98%

Shareholding Pattern

DIIDII increased stake by 82.80%

Shareholding Pattern

FIIFII decreased stake by 22.74%

Bliss GVS Pharma Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹15,12,271+₹10,12,271 (+202.45%)

3 Year

₹23,31,159+₹18,31,159 (+366.23%)

5 Year

₹21,54,917+₹16,54,917 (+330.98%)

₹438.80₹484.90

Circuit Low

Circuit High

₹118.00₹553.00

52-Week Low

52-Week High

Circuit

₹438.80

₹484.90

52-week

₹118.00

₹553.00

Mkt Cap Cr

4,908.81

P/E

17.65

P/B

1.91

ROE

12.01%

D/E

0.04

ROCE

17.02%

Div. Yield

0.46%

EPS(TTM)

9.17

Turnover

0.62

EV/EBITDA

9.08

Net Margin

13.27%

Op. Margin

24.06%

ROA

10.21%

Quick Ratio

4.24

Curr. Ratio

4.85

Mkt Cap Cr

4,908.81

P/E

17.65

P/B

1.91

ROE

12.01%

D/E

0.04

ROCE

17.02%

Div. Yield

0.46%

EPS(TTM)

9.17

Turnover

0.62

EV/EBITDA

9.08

Net Margin

13.27%

Op. Margin

24.06%

ROA

10.21%

Quick Ratio

4.24

Curr. Ratio

4.85

Based on fundamentals, this stock's

Performance

Very Poor

Bliss GVS Pharma has not beaten FD return of 7%

Valuation

Fairly Valued

Bliss GVS Pharma appears to be fairly valued compared to its peers

Earnings

Excellent

Bliss GVS Pharma revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,68,842.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.55	3.27	11.27%	0.00	14.95%	423.36	0.93%	0.44	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,05,607.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	97,364.90	30.58	2.56	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	60.26	10.10	18.21%	0.45	16.70%	10.19	0.20%	0.97	13.72

Bliss GVS Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹927.11	₹809.73	₹770.24	₹751.59
Other Income	₹73.53	₹36.49	₹28.74	₹17.79
Total Revenue	₹1,000.64	₹846.22	₹798.98	₹769.37
Total Expenses	₹808.57	₹720.58	₹652.91	₹663.30
Profit Before Tax	₹189.59	₹125.64	₹116.87	₹106.07
Tax	₹54.86	₹35.38	₹35.29	₹29.34
Profit After Tax	₹134.73	₹90.26	₹81.58	₹76.73
EPS - Basic	₹12.23	₹8.02	₹7.23	₹6.83
EPS - Diluted	₹12.00	₹7.95	₹7.11	₹6.72

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹189.59	₹125.64	₹146.07	₹106.07
Income before WC changes	₹285.46	₹196.38	₹184.24	₹163.99
Change in Assets	-₹158.32	-₹53.98	-₹35.62	-₹75.86
Change in Liabilities	₹53.88	₹2.52	-₹10.95	-₹9.26
Change in WC	-₹104.45	-₹51.46	-₹46.57	-₹85.12
Cash flow from Operations	₹138.72	₹105.91	₹102.82	₹34.31
Cash flow from Investing	-₹38.28	-₹75.59	-₹83.19	-₹7.75
Cash flow from Financing	-₹89.21	-₹30.20	-₹20.89	-₹24.94
Total Cash Flow	₹11.23	₹0.13	-₹1.27	₹1.62
Cash (Start of the year)	₹23.82	₹23.59	₹25.01	₹21.99
Cash (End of the year)	₹35.14	₹23.82	₹23.59	₹25.01

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹546.08	₹477.46	₹400.72	₹459.49
Current Assets	₹946.34	₹823.83	₹810.87	₹697.37
Total Assets	₹1,492.41	₹1,301.29	₹1,211.59	₹1,156.85
Current Liabilities	₹235.54	₹172.16	₹157.41	₹193.26
Net Current Asset	₹710.79	₹651.67	₹653.47	₹504.11
Non-Current Liabilities	₹25.11	₹37.28	₹51.20	₹46.17
Equity Capital	₹1,231.76	₹1,091.85	₹1,002.98	₹917.42
Total Equity & Liabilities	₹1,492.41	₹1,301.29	₹1,211.59	₹1,156.85

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹729.81	₹667.20	₹605.46	₹598.34
Other Income	₹43.72	₹36.22	₹33.50	₹50.77
Total Revenue	₹773.53	₹703.42	₹638.96	₹649.11
Total Expenses	₹637.91	₹609.25	₹527.62	₹533.41
Profit Before Tax	₹133.46	₹94.17	₹70.26	₹115.69
Tax	₹36.59	₹25.20	₹19.61	₹30.21
Profit After Tax	₹96.87	₹68.97	₹50.64	₹85.48
EPS - Basic	₹9.17	₹6.56	₹4.85	₹8.23
EPS - Diluted	₹9.00	₹6.50	₹4.77	₹8.10

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹133.46	₹94.17	₹111.34	₹115.69
Income before WC changes	₹203.80	₹150.61	₹155.59	₹157.11
Change in Assets	-₹82.79	-₹23.72	-₹31.70	-₹67.36
Change in Liabilities	₹40.61	₹0.64	-₹12.38	-₹8.23
Change in WC	-₹42.18	-₹23.08	-₹44.08	-₹75.58
Cash flow from Operations	₹123.16	₹97.21	₹82.17	₹43.81
Cash flow from Investing	-₹51.40	-₹77.87	-₹65.84	-₹12.97
Cash flow from Financing	-₹75.37	-₹26.56	-₹20.76	-₹26.05
Total Cash Flow	-₹3.61	-₹7.23	-₹4.43	₹4.79
Cash (Start of the year)	₹6.85	₹14.17	₹18.60	₹13.82
Cash (End of the year)	₹3.33	₹6.85	₹14.17	₹18.60

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹517.82	₹454.40	₹378.04	₹410.04
Current Assets	₹826.36	₹765.74	₹772.23	₹729.65
Total Assets	₹1,344.18	₹1,220.14	₹1,150.27	₹1,139.69
Current Liabilities	₹168.59	₹125.00	₹114.89	₹153.36
Net Current Asset	₹657.77	₹640.74	₹657.34	₹576.30
Non-Current Liabilities	₹20.40	₹36.51	₹46.94	₹49.34
Equity Capital	₹1,155.19	₹1,058.63	₹988.44	₹937.00
Total Equity & Liabilities	₹1,344.18	₹1,220.14	₹1,150.27	₹1,139.69

* All values are in INR Crore

Qty

Bid

Ask

Qty

464.6

100

Bid Total: 0

Ask Total: 100

Buy orders: 0%

Sell orders: 100%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

44.73

Neutral

ATR (14)

26.33

Neutral

STOCH(9,6)

16.71

Bullish

STOCH RSI (14)

18.88

Bullish

ADX(9)

31.05

Bearish

UO(9)

36.41

Neutral

ROC(12)

-9.76

Bearish

WillR(14)

-83.4

Bullish

Period

Simple value

Exponential vaue

468.75

469.98

10D

493.27

483.01

20D

504.5

485.53

50D

439.27

439.51

100D

338.86

369.68

About Bliss GVS Pharma

ISIN

INE416D01022

Sector Market Cap

₹ 4,908.81 Cr

Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products, other healthcare products, and therapeutic index. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, oral solids, and others. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, NOVOGLIP-5, GVZOLE, and DOXYCYCLINE.

Bliss GVS Pharma Financial Highlights

Revenue: Bliss GVS Pharma reported revenue of ₹1,000.64 crore in FY26 vs ₹846.22 crore in FY25. It showed an increase of 18.25% on a yearly basis.
Operating Profit: Bliss GVS Pharma reported an operating profit of ₹189.59 crore in FY26 vs ₹125.64 crore in FY25. It showed an increase of 50.90% on a year-on-year basis.
Net Profit: Bliss GVS Pharma reported a net profit of ₹134.73 crore in FY26 vs ₹90.26 crore in FY25. It showed an increase of 49.27% on a yearly basis.

Bliss GVS Pharma Quarterly Result Highlights

Bliss GVS Pharma reported revenue of ₹268.15 crore in Mar 2026, compared with ₹236.71 crore in Dec 2025, representing an increase of 13.28% on a quarter-on-quarter (QoQ) basis.
Bliss GVS Pharma reported an operating profit of ₹44.95 crore in Mar 2026, compared with ₹40.90 crore in Dec 2025, representing an increase of 9.90% on a quarter-on-quarter (QoQ) basis.
Bliss GVS Pharma reported a profit of ₹37.00 crore in Mar 2026, compared with ₹24.78 crore in Dec 2025, reflecting an increase of 49.31% on a QoQ basis.
The earnings per share (EPS) of Bliss GVS Pharma stood at ₹12.23 during Mar 2026.